Pediatric Rheumatology

On this page
Comprehensive pediatric rheumatology care
Our specialists care for children of all ages living with rheumatic and inflammatory diseases. These conditions involve connective tissues, joints and muscles. Conditions we treat include:
Autoinflammatory syndromes or periodic fever
Juvenile arthritis
Morphea
Scleroderma
Vasculitis
Rheumatic diseases affect children differently than adults and often require different treatments. In our program, your child receives care from a pediatric rheumatologist who is knowledgeable in the treatment approaches that work best for kids. In fact, our entire team specializes in working with young patients.
Your child's team may include:
Pediatric rheumatologists
Other pediatric specialists, if needed
Nurses
Physical and occupational therapists
Social workers
Comprehensive pediatric rheumatology care
Our specialists care for children of all ages living with rheumatic and inflammatory diseases. These conditions involve connective tissues, joints and muscles. Conditions we treat include:
Autoinflammatory syndromes or periodic fever
Juvenile arthritis
Morphea
Scleroderma
Vasculitis
Rheumatic diseases affect children differently than adults and often require different treatments. In our program, your child receives care from a pediatric rheumatologist who is knowledgeable in the treatment approaches that work best for kids. In fact, our entire team specializes in working with young patients.
Your child's team may include:
Pediatric rheumatologists
Other pediatric specialists, if needed
Nurses
Physical and occupational therapists
Social workers
Locations (dynamic)
Providers (dynamic)

Daniel Soulsby, MD
Pediatric Rheumatology
Geraldina Lionetti, MD
Pediatric Rheumatology
William Bernal, MD, MPH
Rheumatology • Pediatric Rheumatology
Emily Von Scheven, MD
Rheumatology • Pediatric Rheumatology
Awards & achievements
Related conditions & treatments
Conditions
- Autoinflammatory Diseases
- Connective Tissue Disease
- Juvenile Arthritis
- Juvenile Dermatomyositis
- Scleroderma
- Systemic Lupus Erythematosus
- Vasculitis
Treatments
- Physical Therapy
- Clinical Trials
Clinical trials
A Phase 2, Open-Label, Single-Arm Trial of FT819 in Participants With Lupus NephritisOpens in a new window
The primary objective of this trial is to evaluate the efficacy and safety of FT819, comprised of allogeneic T cells that express a CD19-targeted CAR, following bendamustine administration in participants with refractory moderate-to-severe lupus nephritis, as assessed by the proportion of participants who achieve complete renal response (CRR) at Week 26.Trial of Sequential Medications AfteR TNFi Failure in Juvenile Idiopathic ArthritisOpens in a new window
This study is an open-label, randomized, multicenter trial that incorporates a multi-arm design comparing each of 3 non-TNFi (Tumor Necrosis Factor inhibitor) medications to a second TNFi (active control) within a sequential multiple assignment randomized trial design with 2 randomization stages corresponding with clinical decision points...The Pediatric Lupus Nephritis Mycophenolate Mofetil (PLUMM) StudyOpens in a new window
The study is a 1-year 2-part double-blinded placebo controlled 2-arm clinical trial...RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory MyopathyOpens in a new window
RESET-Myositis: Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects with Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory MyopathyA Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric ParticipantsOpens in a new window
This phase II, randomized, double-blind, placebo-controlled study is designed to evaluate the safety, efficacy and pharmacokinetics (PK) of obinutuzumab in adolescent participants (AP) aged 12 to less than 18 with biopsy-confirmed proliferative lupus nephritis (LN). It will also evaluate open label safety and PK of obinutuzumab in pediatric participants (PP), aged 5 to <12 with LN.Observational Study of Pediatric Rheumatic Diseases: The CARRA RegistryOpens in a new window
Continuation of the CARRA Registry as described in the protocol will support data collection on patients with pediatric-onset rheumatic diseases. The CARRA Registry will form the basis for future CARRA studies. In particular, this observational registry will be used to answer pressing questions about therapeutics used to treat pediatric rheumatic diseases, including safety questions.


















